Immunocore Holdings (IMCR) Price & Analysis

Compare

219 Followers

IMCR Stock Chart & Stats

Day’s Range― - ―

52-Week Range$23.15 - $39.33

Previous CloseN/A

Volume28.13K

Average Volume (3M)258.17K

Market Cap

$1.63B

Enterprise Value$1.14B

Total Cash (Recent Filing)$837.03M

Total Debt (Recent Filing)$434.00M

Price to Earnings (P/E)―

Beta1.08

Next Earnings

Nov 05, 2025

EPS Estimate

-0.25

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.20

Shares Outstanding50,233,610

10 Day Avg. Volume283,247

30 Day Avg. Volume258,174

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.70

Enterprise Value/Revenue3.41

Enterprise Value/Gross Profit3.45

Enterprise Value/Ebitda-25.52

Forecast

1Y Price Target

$69.67

Price Target Upside114.17% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe PRISM-MEL-301 trial represents a key catalyst for the brenetafusp program with dose selection expected to drive further development.

Market ExpansionKIMMTRAK remains the standard of care in HLA-A*02:01-positive metastatic uveal melanoma and is now launched in 26 countries, with commercial growth supported by further U.S. uptake, new international launches, and completed pricing negotiations in France and Germany.

Revenue PerformanceKIMMTRAK net product revenue for 1Q25 was $93.9M, above the IMCR-provided consensus estimate.

Bears Say

CompetitionThe complexity, cost, and toxicity profile of autologous TCR T cell therapy underscore the competitive advantage of Immunocore's brenetafusp’s repeatable and combinable bispecific T cell engager mechanism.

Immunocore Holdings News

Immunocore reports Q2 EPS (20c), consensus (21c)

Reports Q2 revenue $97.964M, consensus $92.55M. “We are delighted to announce robust revenue for the first half of...

1d ago

IMCR

Immunocore Holdings Reports Strong Revenue Growth

Immunocore Holdings Plc ( ($IMCR) ) has released its Q2 earnings. Here is a breakdown of the information...

8h ago

IMCR

Immunocore Holdings: Strong Performance and Promising Outlook Drive Buy Rating

Gil Blum, an analyst from Needham, maintained the Buy rating on Immunocore Holdings. The associated price target is...

20h ago

IMCR

Immunocore Holdings: Strong Kimmtrak Performance and Strategic Expansion Justify Buy Rating

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Immunocore Holdings today and set a price...

21h ago

IMCR

Immunocore Holdings’ Promising PRAME-Targeting Therapies Drive Buy Rating

H.C. Wainwright analyst Patrick Trucchio has reiterated their bullish stance on IMCR stock, giving a Buy rating on...

2M ago

IMCR

AMD, Block upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

2M ago

AMD

FLD

Immunocore initiated with a Buy at Deutsche Bank

Deutsche Bank initiated coverage of Immunocore (IMCR) with a Buy rating and $65 price target The firm says...

2M ago

IMCR

Immunocore Holdings Secures Shareholder Approval at AGM

Immunocore Holdings ( ($IMCR) ) has shared an update. On May 15, 2025, Immunocore Holdings plc held its...

3M ago

IMCR

Immunocore price target raised to $86 from $85 at Oppenheimer

Oppenheimer raised the firm’s price target on Immunocore (IMCR) to $86 from $85 and keeps an Outperform rating...

3M ago

IMCR

Immunocore Holdings Reports Strong Q1 2025 Performance

Immunocore Holdings Plc ( ($IMCR) ) has released its Q1 earnings. Here is a breakdown of the information...

3M ago

IMCR

Immunocore price target lowered to $52 from $66 at Barclays

Barclays lowered the firm’s price target on Immunocore (IMCR) to $52 from $66 and keeps an Overweight rating...

3M ago

IMCR

Immunocore Holdings: Strong Sales Growth and Financial Position Justify Buy Rating

Needham analyst Gil Blum maintained a Buy rating on Immunocore Holdings (IMCR – Research Report) today and set...

3M ago

IMCR

Immunocore Holdings: Strong International Growth and Promising Clinical Trials Drive Buy Recommendation

Analyst Tyler Van Buren from TD Cowen maintained a Buy rating on Immunocore Holdings (IMCR – Research Report)...

3M ago

IMCR

Immunocore reports Q1 EPS 10c, consensus (40c)

Reports Q1 revenue $93.9M, consensus $86.45M. “We are thrilled to have achieved strong revenue performance in Q1, marked...

3M ago

IMCR

IMCR FAQ

What was Immunocore Holdings Plc’s price range in the past 12 months?

Immunocore Holdings Plc lowest stock price was $23.15 and its highest was $39.33 in the past 12 months.

What is Immunocore Holdings Plc’s market cap?

Immunocore Holdings Plc’s market cap is $1.63B.

When is Immunocore Holdings Plc’s upcoming earnings report date?

Immunocore Holdings Plc’s upcoming earnings report date is Nov 05, 2025 which is in 89 days.

How were Immunocore Holdings Plc’s earnings last quarter?

Immunocore Holdings Plc released its earnings results on Aug 07, 2025. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of -$0.137 by -$0.063.

Is Immunocore Holdings Plc overvalued?

According to Wall Street analysts Immunocore Holdings Plc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Immunocore Holdings Plc pay dividends?

Immunocore Holdings Plc does not currently pay dividends.

What is Immunocore Holdings Plc’s EPS estimate?

Immunocore Holdings Plc’s EPS estimate is -0.25.

How many shares outstanding does Immunocore Holdings Plc have?

Immunocore Holdings Plc has 50,233,610 shares outstanding.

What happened to Immunocore Holdings Plc’s price movement after its last earnings report?

Immunocore Holdings Plc reported an EPS of -$0.2 in its last earnings report, missing expectations of -$0.137. Following the earnings report the stock price went up 6.629%.

Which hedge fund is a major shareholder of Immunocore Holdings Plc?

Currently, no hedge funds are holding shares in IMCR

Immunocore Holdings Stock Smart Score

Outperform

Fundamentals

Return on Equity

-5.78%

Trailing 12-Months

Asset Growth

3.42%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Immunocore Holdings Plc

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Immunocore Holdings (IMCR) Earnings & Revenues

Historic Earnings Reports

IMCR Company Deck

IMCR Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflected a strong performance in revenue growth and global expansion of KymTrak, as well as promising advancements in clinical trials and a solid financial position. However, challenges in European reimbursement and uncertainties in HIV treatment results were noted. The overall sentiment is predominantly positive due to significant achievements outweighing the challenges.View all IMCR earnings summaries

IMCR Stock 12 Month Forecast

Average Price Target

$69.67

▲(114.17% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"27":"$27","64":"$64","101":"$101","45.5":"$45.5","82.5":"$82.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$100.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":69.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$69.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":36,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$36.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[27,45.5,64,82.5,101],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.99,38.144615384615385,43.29923076923077,48.45384615384616,53.60846153846154,58.76307692307692,63.917692307692306,69.07230769230769,74.22692307692307,79.38153846153845,84.53615384615384,89.69076923076922,94.8453846153846,{"y":100,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.99,35.81153846153846,38.63307692307693,41.45461538461539,44.276153846153846,47.09769230769231,49.91923076923077,52.74076923076923,55.5623076923077,58.38384615384616,61.20538461538462,64.02692307692308,66.84846153846155,{"y":69.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.99,33.221538461538465,33.45307692307693,33.684615384615384,33.91615384615385,34.14769230769231,34.37923076923077,34.61076923076923,34.84230769230769,35.073846153846155,35.30538461538462,35.536923076923074,35.76846153846154,{"y":36,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":39.62,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.88,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.21,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.7,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.49,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.5,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.88,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.37,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.63,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.15,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.65,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.84,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.99,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >